• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

March 3, 2016

View Archived Issues

Other news to note

Sangamo Biosciences Inc., of Richmond, Calif., presented new preclinical data in disease models from its In Vivo Protein Replacement Platform (IVPRP) programs for MPS I (Hurler syndrome) and MPS II (Hunter syndrome). The data demonstrate that the company’s IVPRP approach enabled stable production of therapeutic levels of replacement enzyme from the liver into the circulation and secondary tissues, including the brain, resulting in significant reduction in biomarkers of the disease and, importantly, statistically significant improvements in cognitive function in treated animals. Read More

Neuro-Bio pursuing AChE approach to treat, diagnose Alzheimer’s

LONDON – Neuro-Bio Ltd. has delivered preliminary proof for a previously unknown mechanism it says lies at the heart of the neuronal cell death that typifies Alzheimer’s disease. Read More

Gtreebnt adds GBM drug to burgeoning biopharma pipeline

HONG KONG – South Korea’s Gtreebnt Co. Ltd., a firm that started out researching and developing software, is expanding its drug pipeline, most recently through a deal with a U.S. medical research foundation to develop a product for a lethal form of brain cancer. Read More

House Zika hearing littered with debate over funding request

A House committee met Wednesday to review the current state of preparedness for the Zika virus, a threat that has the attention of a number of federal agencies. However, the matter of a funding request by the Obama administration dominated the discussions, including whether funding for the federal government’s response to the Ebola virus could be diverted for use in the response to the Zika virus. Read More

Germline oncogene mutation causes blood disorder

More than 100 years since the oncogene SRC first came to the attention of the biomedical research community, researchers have for the first time identified individuals with a germline SRC mutation. Read More

Capricor rising: DMD bid at the heart of the matter while agency bears down

Capricor Therapeutics Inc. designed its Duchenne muscular dystrophy (DMD) trial to fit “exactly what the FDA has now mandated they want” in the troubled space, CEO Linda Marbán told BioWorld Today, and the firm’s CAP-1002 represents “a novel take and a practical approach” to the disease. Read More

Califf sets out his top priorities for drug and device safety

In his first Senate budget hearing as FDA commissioner, Robert Califf committed Wednesday to more responsive interaction with lawmakers and a shoring up of the science behind the agency’s actions as he laid out his top priorities concerning drugs and devices. Read More

Horizon, Centauri form joint venture to move Alphamer technology into oncology

DUBLIN – Avvinity Therapeutics Ltd., a newly created joint venture between Horizon Discovery Group plc and start-up firm Centauri Therapeutics Ltd., is getting up to £5.3 million (US$7.4 million) in series A funding to apply Centauri’s Alphamer anti-infectives technology to immuno-oncology indications. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 13, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 13, 2025.
  • Stock merger illustration

    Biontech’s $1.25B Curevac buyout removes mRNA lawsuit uncertainty

    BioWorld
    Three years after litigation started over technology used in an mRNA vaccine for COVID-19, Biontech SE is acquiring its adversary, Curevac NV, through an...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Multiple myeloma illustration

    Another BiTE in autoimmune: Cullinan deals $712M for Genrix asset

    BioWorld
    Cullinan Therapeutics Inc. swept up ex-China rights to a multiple myeloma-targeting BCMAxCD3 bispecific T-cell engager (BiTE) velinotamig from Chongqing Genrix...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe